Descripción del proyecto
Inteligencia artificial y sensores inteligentes para mejorar el tratamiento de la enfermedad pulmonar obstructiva crónica
La enfermedad pulmonar obstructiva crónica (EPOC) es un grupo de enfermedades asociadas con problemas respiratorios que afectan a millones de personas en todo el mundo. Su heterogeneidad requiere métodos de atención y tratamiento personalizados. Con todo, debido a los efectos extrapulmonares y las enfermedades concomitantes, los enfermos no suelen responder a los tratamientos farmacológicos y no farmacológicos. Para abordar este problema, el objetivo del proyecto financiado con fondos europeos TOLIFE es desarrollar una tecnología de inteligencia artificial (IA) para procesar datos de la vida cotidiana de los enfermos de EPOC recopilados por sensores discretos. La plataforma de IA predecirá el agravamiento de la EPOC y evaluará los resultados de salud. Mediante una herramienta de gestión de pacientes, los médicos pueden ofrecer un tratamiento precoz y personalizado, lo que mejorará la calidad de vida de las personas con EPOC.
Objetivo
Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic condition. While COPD is a lung disease, it is mainly the exacerbations and extrapulmonary comorbidities which affect the quality of life, health care costs, and prognosis. The optimal COPD treatment needs to focus on both the characteristics and consequences of the lung disease itself and the diagnosis and treatment of comorbidities. While the severity of lung function impairment is routinely assessed, the exacerbations, the associated comorbidities and limitations in daily life are still significantly underestimated. A personalized approach to COPD management is needed to specifically address the disease, prevent exacerbations, and mitigate its comorbidities to obtain a positive impact on patient health and quality of life.
TOLIFE will clinically validate an artificial intelligence (AI) solution to process daily life patient data captured by unobtrusive sensors to enable optimised personalised treatment, assessment of health outcomes and improved quality of life in COPD patients. The TOLIFE approach to COPD management, targeted to predict and mitigate exacerbations and continuously assess the health outcomes, has the potential to reduce mortality, improve health related quality of life and reduce the healthcare costs.
TOLIFE will develop and clinically validate an AI-based platform for the early prediction of exacerbations and assessment of the health outcomes. Prediction of exacerbations and assessment of health outcomes will be exploited by clinicians through a patient management tool to perform early and personalized treatment. TOLIFE platform will inform through a disease information tool the patient and caregivers about the patient's health status, the specific treatment plan and lifestyle indications. Two clinical studies will be implemented, one to collect data for AI-tools development and the other to validate the effectiveness of TOLIFE to reduce the risk of exacerbations.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinador
56126 Pisa
Italia